Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver

Lai Peng¹,c, Stephanie Piekosa¹, Grace L. Guoᵇ, Xiao-bo Zhongᵃ*,

¹Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA
ᵇDepartment of Pharmacology and Toxicology, School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA
ᶜKey Laboratory of System Biomedicine, Center for Comparative Biomedicine, Institute of Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China

Received 28 April 2016; received in revised form 8 June 2016; accepted 21 June 2016

Abstract The expression of phase-I drug metabolizing enzymes in liver changes dramatically during postnatal liver maturation. Farnesoid X receptor (FXR) is critical for bile acid and lipid homeostasis in liver. However, the role of FXR in regulating ontogeny of phase-I drug metabolizing genes is not clear. Hence, we applied RNA-sequencing to quantify the developmental expression of phase-I genes in both Fxr-null and control (C57BL/6) mouse livers during development. Liver samples of male C57BL/6 and Fxr-null mice at 6 different ages from prenatal to adult were used. The Fxr-null showed an overall effect to diminish the “day-1 surge” of phase-I gene expression, including cytochrome P450s at neonatal ages. Among the 185 phase-I genes from 12 different families, 136 were expressed, and differential expression during development occurred in genes from all 12 phase-I families, including hydrolysis: carboxylesterase (Ces), paraoxonase (Pon), and epoxide hydrolase (Ephx); reduction: aldoketo reductase (Akr), quinone oxidoreductase (Nqo), and dihydropyrimidine dehydrogenase (Dpyd); and oxidation: alcohol dehydrogenase (Adh), aldehyde dehydrogenase (Aldh), flavin monooxgenases (Fmo), molybdenum hydroxylase (Aox and Xdh), cytochrome P450 (P450), and cytochrome P450 oxidoreductase (Por). The data also suggested new phase-I genes potentially targeted by FXR. These results revealed an important role of FXR in regulation of ontogeny of phase-I genes.

© 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: ADH, alcohol dehydrogenase; AKR, aldoketo reductase; ALDH, aldehyde dehydrogenase; CES, carboxylesterase (Ces); DPYD, dihydropyrimidine dehydrogenase; EPHX, epoxide hydrolase; FMO, flavin monooxgenases, Farnesoid X receptor (FXR); NQO, quinone oxidoreductase; P450, cytochrome P450; PON, paraoxonase; POR, cytochrome P450 oxidoreductase

*Corresponding author. Tel.: +1 860 486 2697.
E-mail address: xiaobo.zhong@uconn.edu (Xiao-bo Zhong).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
1. Introduction

Phase-I drug metabolizing enzymes catalyze the oxidation, reduction, and hydrolysis of xenobiotics. A functional transition occurs in liver after birth, and most of the phase-I drug-metabolizing enzymes mature during this period in mouse liver1-3. Changes in expression of some phase-I enzymes during liver maturation in humans have also been reported, including cytochrome P450 (P450s)4-6, carboxylesterase (CES)7,8, paraoxonase (PON)9,10, alcohol dehydrogenase (ADH)11, and flavin monooxygenase (FMO)12-14. The dynamic changes in the ontogenic expression of these genes are thought to be responsible for the substantial pharmacokinetic differences between newborns and adults, and this contributes to differences in therapeutic efficacy and adverse drug reactions in pediatric patients15-19. An in-depth understanding of the regulatory mechanisms of the ontogeny of phase-I enzymes is needed for safer and more effective drug therapy for pediatric patients.

Farnesoid X receptor (FXR) is a bile acid sensing nuclear receptor in maintenance of bile acid homeostasis by feedback inhibition of expression of important genes in bile acid synthesis, for example, CYP7A1, which is the rate-limiting enzyme in the classic pathway of bile acid synthesis, and CYP8B1, which is required for the synthesis of cholic acid20. FXR also plays a role in liver regeneration21. FXR has been confirmed to be knocked out in whole body in this Fxr-null model20. FXR has been found to be associated with changes in FXR-target gene expression in humans26,27. Understanding the regulatory mechanism of FXR on hepatic expression of drug metabolizing enzyme genes in newborns will greatly help us to understand the natural and aberrant development of drug metabolizing enzyme genes in pediatric pharmacology.

In the current study, we used RNA-sequencing to quantify hepatic phase-I metabolizing enzyme gene expression during the developmental period from perinatal stage to adult in both wild-type and a well-established Fxr knockout mouse model20. FXR has been found to be associated with changes in FXR-null mice. Our results revealed the significant differences in Fxr-null livers compared to control livers during postnatal development, and suggested novel roles of FXR in the regulation of phase-I gene developmental expression.

2. Materials and methods

2.1. Animals

We used C57BL/6 mice as the wild-type animals. The animal purchase, breeding and tissue collection for wild-type mice were performed as previously described2. An Fxr-deficient mouse model20 was used to examine the role of FXR in determination of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver. These knockout mice were bred under standard conditions in the Office of Animal Care Facility at the University of Connecticut (Storrs, CT, USA). The use of these mice was approved by the University of Connecticut’s Institutional Animal Care and Use Committee. Liver samples (n=3) from wild-type and Fxr–/– mice were collected at the following 6 ages: day –2 (gestational day 17.5), day 1 (exactly 24 h after birth), and days 5, 20, 25, and 60 (collected at approximately 9:00 AM). These ages represent the periods of prenatal (day –2), neonatal (days 1 and 5), juvenile (days 20 and 25), and young adult (day 60). Due to potential variations caused by the estrous cycle in maturing female mice, only male livers were used in this study. The livers were immediately frozen in liquid nitrogen after removal and stored at –80°C.

2.2. Total RNA extraction, sequencing library construction, and RNA-Seq

RNA extraction, library construction, RNA-Seq, and FASTQ data file collection were performed as previously described2.

2.3. RNA-Seq data analysis

For comparison of phase-I genes between wild-type and Fxr-null mice (Fig. 1A). The total P450 mRNA level decreased more than 12-fold in wild-type mice, yet this increase was less than 5-fold in Fxr–/– mice (Fig. 2). At day 60, the mRNA percentage of phase-I genes within this total expression, we also found dramatic changes around birth and significant differences between wild-type and Fxr-null mice (Fig. 2). At day –2, the mRNA percentage of Akr and Aldh were much lower and the percentage of Adh and Ces were much higher in Fxr-null mice compared with wild-type mice. The percentage of P450 mRNAs in all phase-I genes nearly

In this study, we consider genes with FPKM >1 as expressed. ANOVA was used to test for significant difference in expression between wild-type and Fxr-null mice. P values were adjusted using Benjamini-Hochberg algorithm with a threshold of 0.05. To study the distance of phase-I gene ontogenic pattern between WT and Fxr–/– samples, the average FPKM values from three individual animals were used. For each gene, the FPKM values at the 12 ages (6 ages per genotype) were divided by the mean FPKM of the 12 ages before calculating distance in order to normalize the difference of expression level among genes.

3. Results

3.1. Phase-I gene ontogeny in Fxr–/– mice

For all the P450 genes, significant differences in total mRNA expression between wild-type and Fxr–/– mice were found at ages of days –2, 1 and 5 (Fig. 1A). The expression of total P450s was higher before birth and lower after birth till day 5 in Fxr–/– mice than in wild-type. There was a surge in expression of P450 genes around birth. From days –2 to day 1, the total P450 mRNA level increased more than 12-fold in wild-type mice, yet this increase was less than 5-fold in Fxr–/– mice (Fig. 1A). The total P450 mRNAs reached similar levels from days 20 to 60 in both wild-type and Fxr-null mice. A similar change in total mRNA expression of non-P450 phase I genes between wild-type and Fxr–/– mice was found in Fig. 2.
doubled from days –2 to 1 in wild-type mice, but the P450 percentage was much lower in Fxr-null mice at days 1 and 5. Ces was a family of phase-I genes that showed dramatically higher percentage of expression in Fxr-null mice at perinatal stage of days –2, 1 and 5 (Fig. 2). It is possible that the loss of FXR activated other nuclear receptors or transcription factors in compensation that induced Ces and Aldh expression at neonatal ages. When the age got older, for example at days 25 and 60, both the total mRNA and the composition of different families of phase-I gene expression became similar in wild-type and Fxr-null mice.

After examining the overall effect of Fxr knockout on phase-I gene expression during liver development, we took a further step to assess the ontogeny of individual phase-I genes. Based on UCSC Genes Track mm10, there were 185 phase-I genes in the 12 major families of phase-I genes, and our data showed 136 of them were expressed during liver maturation in wild-type (WT) and Fxr–/– mice (average FPKM 41). Differential expression between wild-type and knockout mice occurred in genes from all 12 phase-I gene families for at least one age during development, suggesting an extensive role of FXR in gene regulation. The distances of developmental pattern between WT and Fxr–/– samples were calculated and phase-I genes were listed in the order from large to small distance in Fig. 3. The genes at the upper part showed more difference in their developmental expression patterns caused by the knockout of Fxr, and the top 10 most altered genes were Cyp26a1, Cyp4a12b, Cyp1a1, Adh6-ps1, Cyp2a4, Cyp7a1, Cyp2d13, Fmo2, Cyp2d37-ps, and Akr1b7. Changes in expression of these genes showed developmental stage-specific effects, for example, Cyp26a1 and Cyp4a12b were only strongly induced or repressed at day 60, Cyp2a4 was induced at adolescent stage, and Akr1b7 was markedly repressed at neonatal stage in the knockout mice compared with wild-type.

3.2. Developmental expression of known FXR target phase-I genes

As we have found out widespread changes of gene expression in Fxr-null mice, especially in those hepatic nuclear receptors and core transcription factors, it would be difficult for us to conclude on the direct role of FXR in regulation of gene transcription.
Therefore, we examined the developmental expression pattern of several known FXR target genes. CYP7A1 is the rate-limiting enzyme in the classic bile acid synthesis pathway, and CYP8B1 is required for synthesis of cholic acid. The known mechanisms of FXR in regulating CYP7A1 and CYP8B1 are as follows. The activation of FXR by bile acids in the liver induces nuclear receptor SHP (Nr0b2), which interacts with HNF4α and LRH-1 and blocks their activation of Cyp7a1 and Cyp8b1 transcription.

Figure 2  Percentages of FPKM values of each phase-I family at ages of days –2, 1, 5, 25, and 60 in both wild-type and Fxr-null mice. WT, wild-type and KO, Fxr-null.

Figure 3  Developmental expression patterns of phase-I genes in livers of wild-type and Fxr⁻/⁻ mice. Heat map of expression profiles are drawn for all expressed phase-I genes (FPKM > 1). The genes are listed in an order based on the distance of ontogenic pattern between WT and Fxr⁻/⁻ samples, with the ones at the top showing patterns most altered in Fxr-knockout mice.
On the other hand, activated FXR in the intestine can induce intestinal FGF-15 (FGF-19 in human), which circulates to liver and bind FGFR4 to activate JNK phosphorylation pathway and suppress Cyp7a1 and Cyp8b1 expression. Our results demonstrated that Cyp7a1 mRNA level was significantly induced at all 6 ages in Fxr knockout mice, and the induction fold change was largest at day 20, indicating the repression of CYP7A1 by FXR was more critical at day 20 (Fig. 5A). Although it was proposed that CYP7A1 and CYP8B1 were under the same FXR regulatory pathway, Cyp8b1 mRNA level was not significantly altered in Fxr-null mice (Fig. 5B). So the regulation of FXR on Cyp8b1 gene was relatively weak, and there might be other critical regulatory factors that maintain the expression of CYP8B1 in the absence of FXR. The expression of SHP, the direct target gene of FXR in the liver pathway for regulation of CYP7A1 and CYP8B1, was only reduced at young ages in Fxr-null mice, also suggesting developmental stage-specific effect of FXR (Fig. 5C). And the result indicated that the induction of CYP7A1 at day 60 was mainly due to failed suppression from the FXR intestinal pathway. Taken together, these data provided new insights for the role of FXR in regulation of its target gene expression.

### 3.3. Phase-I genes potentially targeted by FXR

Our data also suggested new phase-I genes potentially targeted by FXR. Previous study has shown that bile acid and FGF19 treatment decreased PON1 mRNA level. And in our Fxr-null mice, the Pon1 mRNA level was induced during development (Fig. 6A), which further supported the role of FXR in repression of PON1 expression, probably through intestinal FXR function. In

---

**Figure 4** Expression patterns of CYP3A11 during liver development. Data are expressed as mean FPKM and SEM of three individual animals.

**Figure 5** Expression patterns of (A) Cyp7a1, (B) Cyp8b1 and (C) Shp during liver development. Data are expressed as mean FPKM and SEM of three individual animals.

**Figure 6** Expression patterns of (A) Pon1, (B) Pon2, and (C) Pon3 during liver development. Data are expressed as mean FPKM and SEM of three individual animals.
addition, the induction of Pon2 and Pon3 mRNA in Fxr-null mice was also observed (Fig. 6B and C), Pon1/2/3 genes are located next to each other in the genome and it is highly likely that they are co-regulated by FXR.

Besides Cyp7a1, only three other genes, Aldh5a1, Aldh6a1 and Dpyd, showed significant changes of expression at all 6 ages in Fxr-null mice (Fig. 7). ChIP-Seq study identified FXR binding on Aldh5a1 gene. So the mRNA basal expression of these phase-I genes during development may be repressed by FXR. However, further study is needed to validate the direct involvement of FXR in control of the expression of these genes.

4. Discussion

In this study, comparison of ontogeny of hepatic phase-I genes in wild-type and Fxr-knockout mice by RNA-Seq revealed important roles of FXR in regulating developmental expression of phase-I genes. The loss of FXR resulted in significant changes of phase-I gene expression from all 12 major families, and suggested new phase-I genes potentially targeted by FXR.

The baby mice take milk from their mother, which has a high fat content. Bile acids are necessary for the absorption of fat, and they are mainly synthesized and secreted at the immediate perinatal period to facilitate milk absorption. As the endogenous ligands for FXR, bile acids activated FXR signaling may be important for regulating perinatal gene expression in liver. Studies have shown that FXR functions to initiate the expression of major bile acid transporters in newborn mice. FXR is critical for the “day 1 surge” pattern of Ntcp, Bsep, and Mdr2 in newborn mouse liver. And here in our results, FXR is also critical for the “day 1 surge” of total phase-I expression (Fig. 1). The total mRNA of P450s was expressed significantly lower at newborn ages (days 1 and 5) in Fxr-null mice.

For the phase-I gene expressions most altered by the loss of FXR, Cyp26a1 mRNA was highly induce at day 60. CYP26A1 functions in the catabolism of retinoic acid, and is normally induced by increased retinol or retinoic acid levels. It is possible that this gene induction is a result of altered metabolism in retinoic acid pathway. The second gene in the distance list, Cyp4a12, was markedly suppressed at day 60 (Fig. 3). Cyp4 family gene is known to be regulated by PPAR receptors, and FXR can influence PPAR expressions. So this may also be an indirect effect of Fxr knockout. Many genes identified in this project may be indirectly regulated by FXR. With a complicated regulatory network, it is difficult for us to conclude on the role of FXR in some of the changes of expression patterns. ChIP-Seq technology using specific anti-FXR antibody is a powerful tool to identify genome-wide FXR binding sites. Future studies combining the current data with ChIP-Seq experiments during liver development would provide important information to understand the regulatory mechanism of FXR on ontogeny of phase-I genes.

Quantifying the developmental expression is an initial step to study ontogeny of phase-I genes. It utilized advanced technology to generate an overall picture of gene expression, and revealed potential fields of interest that await further researches. For example, future studies to over-express FXR or treat the animals with FXR agonists during development may complement the loss-of-function study and help differentiate the direct and indirect effects of FXR in regulating development gene expression. Characterization of functional FXR polymorphisms in human and their roles in bile acid homeostasis will help to understand the important roles of FXR. Altogether, these studies would enable a more profound understanding of liver development and ontogeny of phase-I genes, and provide a foundation to assist researchers in understanding developmental susceptibility and improving the safety and effectiveness of pharmacotherapy in children.

Acknowledgments

This study was supported in the part by the U. S. National Institutes of Health National Institute for Environmental Health Sciences [Grant R01ES-019487 to Xiao-bo Zhong] and U. S. National Institutes of Health National Institute of General Medical Sciences [Grants R01GM-087376 and R01GM118367 to Xiao-bo Zhong].

References

1. Peng L, Cui JY, Yoo B, Gunewardena SS, Lu H, Klaassen CD, et al. RNA-sequencing quantification of hepatic ontogeny of phase-I enzymes in mice. Drug Metab Dispos 2013;41:2175–86.
2. Peng L, Yoo B, Gunewardena SS, Lu H, Klaassen CD, Zhong XB. RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development. Drug Metab Dispos 2012;40:1198–209.
3. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965–74.
4. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573–82.
Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver

5. Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos. 2008;36:1587–93.

6. Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol. 2009;78:184–90.

7. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJY, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenetic expression, inter-individual variability and differential hydrolysis of osetamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2009;77:238–47.

8. Zhu HJ, Appel DJ, Jang Y, Markowitz JS. Age- and sex-related impact on disposition in neonates and young children. J Pediatr. 2006;149:764–72.

9. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Expression of human paraoxonase (PON1) during development. Pharmacogenomics 2003;4:335–64.

10. Smith M, Hopkinson DA, Harris H. Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet 1971;34:251–71.

11. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monoxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002;51:236–43.

12. Cherrington NJ, Cao Y, Cherrington JW, Rose RL, Hodgson E. Physiological factors affecting protein expression of flavin-containing monoxygenases 1, 3 and 5. Xenobiotica 1998;28:673–82.

13. Hines RN. Developmental and tissue-specific expression of human flavin-containing monoxygenases 1 and 3. Expert Opin Drug Metab Toxicol 2006;2:41–9.

14. Kears GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157–67.

15. Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 2013;452:3–7.

16. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250–67.

17. Blake MJ, Castro L, Leeder JS, Kears GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005;10:123–38.

18. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 2007;21:169–75.

19. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731–44.

20. Li G, Guo GL. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharm Sin B 2015;5:93–8.

21. Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 2015;5:135–44.

22. Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B 2015;5:158–67.

23. Kliever WA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23:687–702.

24. Jung D, Mangelsdorf DJ, Meyer UA. Pregnan X receptor is a target of farnesoid X receptor. J Biol Chem 2006;281:19081–91.

25. Marzolini C, Tirone RA, Gervasini G, Poonkuzhali B, Assem M, Lee W, et al. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 2007;21:1769–80.

26. Kovacs P, Kress R, Rocha J, Kurtz U, Miel JF, Nervi F, et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 2008;48:116–24.

27. Lambert G, Amar MJ, Guo G, Brewer Jr HB, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003;278:2563–70.

28. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001;276:39411–8.

29. Claudel T, Staelens B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020–30.

30. Shih DM, Kast-Weibel HR, Wong J, Xia YR, Edwards PA, Lasis AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J Lipid Res 2006;47:384–92.

31. Lee J, Seek S, Yu P, Kim K, Smith Z, Rivas-Astroza M, et al. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 2012;56:108–17.

32. Cui JY, Aleksunes LM, Tanaka Y, Fu ZD, Guo Y, Guo GL, et al. Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. Am J Physiol Gastrointest Liver Physiol 2012;302:G979–96.

33. Renga B, Mencarelli A, Migliorati M, Cipriani S, D’Amore C, Distruiti E, et al. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflamm Res 2011;60:577–87.

34. Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, Guo GL. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010;51:1410–9.